Multiple sclerosis (MS) is a severe autoimmune disease that affects mainly young individuals. It is estimated that there are 17-20,000 affected persons in the Czech Republic. Currently, MS remains an incurable but treatable disease. As of now, there are many drugs that are able to reduce the inflammatory part of the disease that prevails in its initial phases. The problem is the great variability of the severity of clinical course (from relatively benign to severe malignant courses) and different responses of particular patients to particular drugs. A personalized approach with long life monitoring and adjustment of treatment according to the activity of the disease is essential. From this point of view registries represent one of the most important source of long term data that is used for evaluation of effectiveness and safety of different drugs in areal life setting. The objective of this study is to compare effectiveness and safety profile in MS patients treated with a different Disease Modifying Drugs (DMDs) and Ocrelizumab using data from the real clinical practice from the Czech national multiple sclerosis patient registry (ReMuS).
Study Type
OBSERVATIONAL
Enrollment
17,478
Administered as part of routine clinical practice.
IMPULS Endowment Fund
Prague, Czechia
Effectiveness in relapses
Measurement of annualized relapse rate (ARR) in patients on different DMDs.
Time frame: 1 year from DMD initiation
Effectiveness EDSS
Description of disability measured by Expanded Disability Status Scale (EDSS) of values 0 to 10, where 0 represents no neurological disability due to multiple sclerosis (MS), and 10 represents death due to MS. The EDSS is commonly used among clinicians, and described by Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11): 1444-1452.
Time frame: 1 year from DMD initiation
Description of baseline characteristics of patients treated by different DMDs at the time of DMT initiation
Baseline characteristics (age, sex, disease duration, previous treatment, type of MS) of patients treated with different DMDs
Time frame: Baseline
Description of termination of different DMDs treatment
Number of patients that terminate treatment on particular DMDs
Time frame: Day of DMD termination, assessed up to 15 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.